From the resurgence of biotech to the fierce battle in the metabolic space, and the launches set to reshape therapy areas, the year ahead promises big shifts. https://vist.ly/55986 Our 2026 Preview Report dives into: - Top-selling drugs and biggest companies - The most valuable pipeline projects - Market forces driving M&A and investment - Regulatory changes shaping approvals Download the full 2026 Preview Report for deeper insights.
Evaluate Ltd
Information Services
Evaluate provides trusted commercial intelligence and predictive analytics to the pharmaceutical industry
About us
Evaluate provides trusted commercial intelligence and forecasting models for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global biopharma market to drive better decisions. Evaluate solutions give you the time and confidence to turn understanding into insight, and insight into action. Evaluate Pharma - the trusted global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2030, company financials, pipelines, deals and more. Evaluate Omnium - provides a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, delivering game-changing insight into pharma asset potential. Forecasting Solutions - Ensure precise and efficient forecasting at every stage of your product lifecycle. Our comprehensive suite of forecasting solutions tailored to the pharmaceutical industry, including software, cloud-based platforms, custom-built models, advanced analytics and data. Our forecasting solutions support forecasters through new product planning, launch, and commercialisation. CDMO Intelligence - Access CDMO screening, molecular landscape insights, detailed manufacturing capabilities, and accurate volume forecasts. You’ll have a wealth of data and industry insights at your fingertips, backed by gold standard financial forecast methodologies. Consulting and Analytics - Evaluate’s consulting and analytics team is here to help clients address unique scientific, clinical and commercial challenges. We answer key asset, portfolio strategy, and corporate strategy-related business questions, powered by the combined resources of Norstella, one of the world’s largest pharma intelligence solutions providers. Evaluate’s combination of leading data sources, deep pharma expertise, robust methodologies, data science and real-world data will ensure your teams make the right decisions to drive your growth.
- Website
-
http://www.evaluate.com
External link for Evaluate Ltd
- Industry
- Information Services
- Company size
- 51-200 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 1996
- Specialties
- pharma business analysis, pharma licensing deals, pharma consensus forecasts, biotech business analysis, pharma competitive intelligence, medtech consensus forecasts, pharma business developement, pharma R&D analysis, pharma data, pharma forecasting models, Real World Data, Pharma portfolio strategy, Pharma Consulting, and BD&L consulting
Locations
-
Primary
Get directions
3 More London Riverside
London, SE1 2RE, GB
-
Get directions
1 Pennsylvania Plaza
#2505
New York, NY 10119, US
-
Get directions
Akasaka Garden City 4F, 4-15-1 Akasaka,
Tokyo, Tokyo 107-0052, JP
Employees at Evaluate Ltd
Updates
-
Make every move count with strategic insight that drives investment success. https://vist.ly/558y2 Whether you're evaluating potential partners, analyzing market potential, or planning your next move, our data-driven insights and expert analysis ensure you stay ahead of the curve. Explore solutions for financial services. #EvaluateForFinance
-
A good read from Fierce Biotech on how China-based biotechs are approaching pricing as buyers rely more on AI and local market insight. https://vist.ly/555ds The article references data from Evaluate and Norstella and reflects what we’re seeing across deal activity: • Pricing expectations rising with asset maturity • More emphasis on China-specific intelligence • Faster, more focused diligence Take 5 minutes and read this helpful perspective on how cross-border biotech dealmaking continues to evolve.
-
“By the beginning of the next decade, orphan drugs could account for about a fifth of the entire prescription drug market.” Melanie Senior and Andreas Hadjivasiliou discuss this outlook in "Orphan Drugs: A safe(r) passage amid stormy waters?", including what’s driving current projections and how the market may evolve. Watch the on‑demand webinar: https://vist.ly/554vu
-
No two assets — or decisions — are the same. https://vist.ly/54y3k From early‑stage evaluation to post‑launch forecasting, Sheila Li works with clients to build customized frameworks that support confident, data‑driven choices at every stage of the asset lifecycle. Meet the expert behind the insights at the link in this post.
-
-
DOWNLOAD: The lines between pharma and biotech are blurring. https://vist.ly/54tjr As funding tightens and policy shifts, both sectors are adapting, with biotechs becoming leaner and more independent, and pharma exploring new business models and direct-to-patient channels. Convenience, affordability, and access are now as important as innovation. Check out the article at the link in this post.
-
-
Most teams are still making critical portfolio decisions with incomplete or internally biased forecasts. That is where value gets lost. Evaluate Advisory helps you quantify real commercial opportunity with independent, evidence-backed forecasting and valuation: • Market sizing across geographies and patient populations • Scenario-based NPV and rNPV modeling • Clear, defensible assumptions for investors and partners Stop second-guessing asset value. Start making confident, data-driven decisions. Find out more about our consulting & Analytics team: https://vist.ly/54q9c
-
FDA oversight remains an important consideration in orphan drug outlooks. Melanie Senior and Andreas Hadjivasiliou discuss how regulatory factors are incorporated into projections through 2032 in "Orphan Drugs: A safe(r) passage amid stormy waters?" View the on‑demand webinar here: https://vist.ly/54nrt
-
The biggest outlook in pharma is back. https://vist.ly/54jmd If you are making decisions in today’s market, you cannot afford to miss this. Registration is now open for the World Preview 2026 webinar, featuring extended forecasts to 2032 and the insights you need to stay ahead. 📅 June 16 | 3pm London | 10am New York Register now: https://vist.ly/54jmd
-
-
Biopharma deal-making did not slow down in 2025. It evolved. https://vist.ly/54ihk Total alliance value hit $269.5B, with larger, more strategic partnerships driving a 37% increase in average deal size. M&A value surged to $201.2B, fueled by a handful of mega deals reshaping the market. Q4 led the charge across alliances, M&A, and financing. Momentum is building, not cooling. Get the full breakdown of deal structures, quarterly trends, and where capital is flowing next.
-